PathoQuest, a Paris, France-based genomic expert company, closed an €8M financing.
The funding includes a venture loan from Norgine Ventures, financing from historical investors Kurma Partners, Idinvest Partners and strategic partner, Charles River Labs and a new venture investor, investiere. The financing also includes €427K in non-dilutive funding from the French Public Program Investissement d’Avenir (PIA3) – concours Innovation i-Nov which is dedicated to bioproduction.
The company intends to use the funds to continue to develop its Biologics Genomic Services business and the advancement of efforts with iDTECT Blood in a clinical setting.
A spin out of Institut Pasteur led by Jean-Francois Brepson, CEO, PathoQuest is a life sciences company combining a Next-Generation Sequencing (NGS) platform and a proprietary sample preparation process which is applicable to several types of samples with a proprietary pathogen genome sequence database and automated analysis pipeline. The solution provides microbiologists and clinicians with a comprehensive analysis covering all known clinically relevant human pathogens.
PathoQuest has developed iDTECT™ Blood, a CE IVD metagenomic test for clinical infectious disease diagnosis.
Based on its technological platform, the company also provides biopharmaceutical companies with Biological Genomic Services.